JP2020500870A5 - - Google Patents

Download PDF

Info

Publication number
JP2020500870A5
JP2020500870A5 JP2019529218A JP2019529218A JP2020500870A5 JP 2020500870 A5 JP2020500870 A5 JP 2020500870A5 JP 2019529218 A JP2019529218 A JP 2019529218A JP 2019529218 A JP2019529218 A JP 2019529218A JP 2020500870 A5 JP2020500870 A5 JP 2020500870A5
Authority
JP
Japan
Prior art keywords
composition
dissolution test
cancer
acid
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019529218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500870A (ja
Filing date
Publication date
Priority claimed from KR1020160161931A external-priority patent/KR20180062063A/ko
Application filed filed Critical
Publication of JP2020500870A publication Critical patent/JP2020500870A/ja
Publication of JP2020500870A5 publication Critical patent/JP2020500870A5/ja
Pending legal-status Critical Current

Links

JP2019529218A 2016-11-30 2017-07-07 乳酸カルシウム組成物および使用法 Pending JP2020500870A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2016-0161931 2016-11-30
KR1020160161931A KR20180062063A (ko) 2016-11-30 2016-11-30 서방형 항암용 약학 조성물
PCT/IB2017/054091 WO2018100442A1 (en) 2016-11-30 2017-07-07 Calcium lactate compositions and methods of use

Publications (2)

Publication Number Publication Date
JP2020500870A JP2020500870A (ja) 2020-01-16
JP2020500870A5 true JP2020500870A5 (https=) 2020-08-20

Family

ID=62242802

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019529218A Pending JP2020500870A (ja) 2016-11-30 2017-07-07 乳酸カルシウム組成物および使用法

Country Status (12)

Country Link
US (3) US11285121B2 (https=)
EP (1) EP3547999A4 (https=)
JP (1) JP2020500870A (https=)
KR (3) KR20180062063A (https=)
CN (2) CN110087632B (https=)
AR (1) AR110302A1 (https=)
AU (2) AU2017368901B2 (https=)
MX (1) MX2019006291A (https=)
MY (1) MY206468A (https=)
PH (1) PH12019501199A1 (https=)
TW (2) TWI827535B (https=)
WO (1) WO2018100442A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019138379A1 (en) 2018-01-12 2019-07-18 Metimedi Pharmaceuticals Co., Ltd. Methods of treating chronic inflammatory diseases
CN112512406A (zh) * 2018-06-06 2021-03-16 梅西莫股份有限公司 阿片类药物过量监测
US12097043B2 (en) 2018-06-06 2024-09-24 Masimo Corporation Locating a locally stored medication
KR101998246B1 (ko) * 2018-08-22 2019-07-10 주식회사 메타파인즈 금속이온에 결합된 이온화합물을 포함하는 암 치료용 약학 조성물
US11464410B2 (en) 2018-10-12 2022-10-11 Masimo Corporation Medical systems and methods
DK3980001T3 (da) * 2019-06-10 2025-12-01 Ponce De Leon Health Designated Activity Company Depotsammensætninger af alfa-ketoglutarat
EP4093507A4 (en) * 2020-01-24 2024-02-28 Barkey, Daniel, Q. WEIGHT LOSS COMPOSITIONS AND METHODS
WO2021188999A2 (en) 2020-03-20 2021-09-23 Masimo Corporation Health monitoring system for limiting the spread of an infection in an organization
CA3187241A1 (en) * 2020-08-03 2022-02-10 Krishna Murthy Bhavanasi Pharmaceutical compositions comprising ribociclib
KR102840190B1 (ko) * 2022-04-19 2025-07-29 (의) 삼성의료재단 생리활성물질 전달체
WO2024242545A1 (ko) * 2023-05-23 2024-11-28 (주) 메티메디제약 칼슘 락테이트를 활성 성분으로 포함하는 암 백신 조성물 및 그 용도
EP4502147A1 (en) 2023-07-31 2025-02-05 M2Rlab SL Method for the polarization of cells to a new m2 phenotype and uses of said m2-polarized cells

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3279997A (en) * 1963-10-22 1966-10-18 Herbert D Schneyer Enteric coated calcium lactate tablets containing an antihistamine and thiamine chloride
JPS4837815B1 (https=) * 1970-09-25 1973-11-14 Yamanouchi Pharma Co Ltd
DE68905424T2 (de) * 1988-08-22 1993-06-24 Takeda Chemical Industries Ltd Alpha-glucosidaseinhibitor zur foerderung der calciumabsorption.
US5980951A (en) * 1996-04-10 1999-11-09 Merck & Co., Inc. Oral coated active drugs
DE10233229A1 (de) * 2002-07-22 2004-02-12 S.K. Enterprise Gmbh Pharmazeutische Zusammensetzung zur Senkung des Triglyceridspiegels
US20060118003A1 (en) * 2002-12-17 2006-06-08 Yukoh Sakata Light-blocking agent and film-forming composition
ES2255429B1 (es) * 2004-10-25 2007-08-16 Italfarmaco, S.A. Composiciones farmaceuticas bucodispersables.
US20060280795A1 (en) * 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
CN1961957A (zh) * 2005-11-09 2007-05-16 天津市礼人医药科技有限公司 一种抗衰老结肠吸收制剂
UA95093C2 (uk) 2005-12-07 2011-07-11 Нікомед Фарма Ас Спосіб одержання кальцієвмісної сполуки
US20070196399A1 (en) 2006-02-21 2007-08-23 Shin-Etsu Chemical Co., Ltd. Enteric-coated preparation covered with enteric coating material for site-specific delivery of drug to site within the small intestine
JP2008044927A (ja) * 2006-02-21 2008-02-28 Shin Etsu Chem Co Ltd 小腸内部位特異的薬物デリバリーのための腸溶性コーティング基剤で被覆した腸溶性製剤
EP2114380A1 (en) * 2007-01-25 2009-11-11 Panacea Biotec Ltd. Modified release pharmaceutical composition and a process of making the same
CN101139281A (zh) * 2007-10-16 2008-03-12 陈杰 纳米乳酸钙及其制备方法
CN101385696B (zh) * 2008-07-29 2012-01-04 北京圣医耀科技发展有限责任公司 含依托泊苷的海藻酸钠微球血管栓塞剂及制备方法与用途
CA2754684A1 (en) 2009-03-26 2010-09-30 Pulmatrix, Inc. Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
US8247000B2 (en) * 2009-04-10 2012-08-21 Cypress Pharmaceutical, Inc. Phosphate-binding magnesium salts and uses thereof
EP2599477A1 (en) 2011-11-30 2013-06-05 Lunamed AG 4-Phenylbutyric acid sustained release formulation
CN102823872B (zh) * 2012-08-22 2014-01-15 安徽泰格生物技术股份有限公司 包膜乳酸钙颗粒及其制备方法
WO2014145219A1 (en) * 2013-03-15 2014-09-18 Cerolife Llc Orally administrable compositions comprising calcium
CN103316033B (zh) * 2013-07-03 2015-07-15 康晓飞 一种凝胶剂及其用途
EP3146334B1 (en) * 2014-05-23 2019-08-14 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for determining whether a patient will achieve a response after radiation therapy
CN104523612A (zh) * 2014-12-05 2015-04-22 海南卫康制药(潜山)有限公司 一种乳酸钙组合物咀嚼片及其制备方法
KR101683635B1 (ko) * 2014-12-29 2016-12-09 가천대학교 산학협력단 락테이트 금속염을 포함하는 암 치료용 약학 조성물
CN107898808B (zh) * 2017-10-31 2021-04-27 华仁药业股份有限公司 小儿用静脉营养制剂

Similar Documents

Publication Publication Date Title
JP2020500870A5 (https=)
KR102512475B1 (ko) 칼슘 락테이트 조성물 및 사용 방법
JP2010522742A (ja) タクロリムスの修飾型剤形
TW201210593A (en) Compositions and methods for treating centrally mediated nausea and vomiting
JP2010533714A5 (https=)
JP6598841B2 (ja) ツーピース硬カプセル用の耐酸性バンド溶液
EA013741B1 (ru) Дисперсии наночастиц такролимуса с повышенными растворимостью в воде и биодоступностью, способы их приготовления и применения
JP2013537903A (ja) カラノライド、その誘導体及び類似体についての医薬組成物並びにそれを製造するための方法
WO2009068708A2 (es) Composición farmacéutica de liberación sostenida de somatostatina o un análogo suyo
JP2021152050A (ja) フマル酸ジメチルを含む医薬ビーズ製剤
US20160193155A1 (en) Pulsatile-release dosage form
TWI834862B (zh) 用於經口投遞滲透性不良蛋白質、肽及小分子之調配物
JP2016514706A5 (https=)
RU2015128028A (ru) Длинноцепочечные липосбалансированные сложные эфиры тестостерона для пероральной доставки
WO2022103833A1 (en) Metal-organic framework mediated macromolecule delivery system
TH1901003139A (th) องค์ประกอบแคลเซียม แลคเตตและวิธีการใช้
JP2017518980A (ja) タペンタドールを含む、改変防止即時放出カプセル製剤
JP7640453B2 (ja) 医薬製剤およびその製造方法
TW201215412A (en) Stable pharmaceutical composition
JP2019517490A (ja) がん療法のためのメトロノミック経口ゲムシタビン
CN109662968A (zh) 含A-失碳-5α雄甾烷化合物的升白制剂及其应用
KR101819310B1 (ko) 사이클로스포린을 포함하는 약학 조성물
AU2016280148A1 (en) Extended release Capecitabine capsules
US20060269596A1 (en) Controlled release compositions comprising an acylanilide
CA2649893A1 (en) Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis